Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced results from the ENZAMET trial presented at the 2026 ASCO Annual Meeting. The analysis demonstrates that the ...
A groundbreaking blood test could enable doctors to identify failing prostate cancer treatment earlier, a trial found. Experts believe this discovery could lead to personalised therapies and extend ...
A new UCL-led international trial will assess whether AI can perform as well as expert radiologists at detecting prostate ...
Diagnostic tools based on artificial intelligence are now making their way into Norwegian hospitals. AI can independently read X-ray images and detect bone fractures, or assess cancer tumors in both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results